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Abstract 1 
Hepatitis C virus encodes two enveloped glycoproteins, E1 and E2, which 2 
are involved in viral attachment and entry into target cells. We have obtained in 3 
insect cells infected by recombinant baculovirus a chimeric secreted recombinant 4 
protein, E1341E2661, containing the ectodomains of E1 and E2. The described 5 
procedure allows the purification of approximately 2 mg of protein from 1 L of 6 
culture media. Sedimentation velocity experiments and SDS-PAGE in the absence 7 
of reducing agents indicate that the protein has a high tendency to self-associate, the 8 
dimer being the main species observed. All the oligomeric forms observed maintain 9 
a conformation which is recognized by the conformation-dependent monoclonal 10 
antibody H53 directed against the E2 ectodomain. The spectroscopic properties of 11 
E1341E2661 are those of a three-dimensionally structured protein. Moreover, the 12 
chimeric protein is able to bind to human antibodies present in HCV-positive human 13 
sera. Accordingly, this chimeric soluble polypeptide chain may be a valuable tool to 14 
study the structure-function relationship of HCV envelope proteins. 15 
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Introduction 1 
 Hepatitis C virus (HCV) is a major cause of chronic hepatitis, liver cirrhosis, 2 
and hepatocellular carcinoma worldwide [1]. This enveloped and positive-stranded 3 
RNA virus belongs to the Hepacivirus genus of the Flaviviridae family [2]. There is 4 
no vaccine for HCV, and current antiviral therapies are based on the use of 5 
polyethylene glycol-modified interferon in combination with ribavirin. However, 6 
these treatments are expensive, relatively toxic, and effective in only half of the 7 
treated patients [3]. 8 
 Structural and non-structural viral proteins are produced by cleavage of a 9 
polyprotein precursor by both host cell signal peptidases and viral proteinases [4, 5]. 10 
The envelope glycoproteins, E1 and E2 are classified as type I integral 11 
transmembrane proteins with a N-terminal ectodomain and a C-terminal hydrophobic 12 
anchor domain. During their synthesis, the ectodomains of HCV envelope 13 
glycoproteins are targeted to the endoplasmic reticulum lumen, where they are highly 14 
modified by N-linked glycosylation [6]. In vitro expression studies have shown that 15 
both glycoproteins associate to form a stable heterodimer, which accumulate in the 16 
endoplasmic reticulum, the proposed site for HCV assembly and budding [7].  17 
 This heterodimer is thought to be the functional complex at the surface of the 18 
virus [7], being involved in the virus entry into the cell. E2 seems to be the protein 19 
responsible for the interaction with cell receptors that include the CD81 tetraspanin, 20 
the scavenger receptor BI (SR-BI) and Claudin-1, a tight junction protein that 21 
recently has been proposed as co-receptor in a late step for HCV entry [8-10]. Also, 22 
E2 elicits production of neutralizing antibodies against the virus, and is involved in 23 
viral morphogenesis [9, 11]. Antibodies specific for epitopes within one of the 24 
hypervariable regions of E2 have been reported to inhibit binding of E2 to cells and 25 
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to block HCV infectivity in vitro and in vivo [12-14]. The role of E1 (residues 192 to 1 
383) in HCV infection remains unclear; however, several antibodies directed against 2 
E1 were able to neutralize cell entry, presumably at a stage distinct from receptor 3 
binding [15-17]. E1 and E2 are major candidates for anti-HCV vaccine because they 4 
may harbour neutralizing antibody epitopes [18 , 19]; the envelope proteins may also 5 
work as a vaccine for chronically infected individuals who have a low immune 6 
response to E1 and E2 [20]. 7 
 Because of the difficulties in propagating HCV in cell culture, many aspects 8 
of HCV life cycle remain unclear. A major advance in the investigation of HCV entry 9 
was the development of pseudoparticles (HCVpp), consisting of native HCV 10 
envelope glycoproteins E1 and E2 assembled into retroviral core particles [21, 22]. 11 
This system is potentially powerful to identify and characterize molecules that block 12 
HCV entry. Furthermore, data obtained with HCVpp can also now be confirmed with 13 
the help of the recently developed cell culture system that allows efficient 14 
amplification of HCV [23, 24]. 15 
 Knowledge of the three-dimensional structure of HCV envelope proteins E1 16 
and E2 will be of great value in the quest for a vaccine, in explaining existing data 17 
and in designing novel experiments. Despite that E1 and E2 have been expressed in 18 
several prokaryotic [25] or eukaryotic [26-29] cell lines, few data concerning the 19 
structure of isolated proteins have been obtained. Although the E2 ectodomain has 20 
been characterized as an independent folding unit [30], several studies indicate that 21 
the folding of E1 depends on the presence of E2 protein, and thus it should be 22 
characterized once the E1E2 complex has fully folded [31]. However, the only 23 
available structural data of the E1E2 complex are based on the use of conformation 24 
dependent monoclonal antibodies using the complete envelope glycoproteins 25 
 5
associated with partially purified HCVpp [21, 32]. Moreover, the reconstitution of 1 
“native” E1E2 heterodimers in liposomes has been reported [33]. However, only 1-5 2 
g of pure protein for every 107 cells could be obtained, which does not seem enough 3 
to achieve a full biochemical characterization of this protein in solution. In order to 4 
circumvent all these problems, we have designed a chimeric protein containing the 5 
E1 and the E2 ectodomains connected by a small hydrophilic peptide (E1341E2661). In 6 
this work, we described the production and characterization of E1341E2661 using the 7 
baculovirus/insect cell system. Only the chimeric polypeptide which is secreted 8 
soluble to the cell supernatant was purified to homogeneity. Approximately 2 mg of 9 
protein from 1 L of culture media can be purified. The protein has a high tendency to 10 
self-associate, the dimer being the main species observed. The spectroscopic 11 
properties are those of a folded polypeptide chain. Moreover, the chimeric protein is 12 
able to bind to human antibodies present in HCV-positive human sera.  13 
14 
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Materials and methods 1 
 2 
Plasmids construction 3 
The cDNAs encoding E1 (residues 192-341) and E2 (residues 380-661) 4 
ectodomains were obtained by RT-PCR from the viral RNA of a strain 1HCV-PT, 5 
genotype 1a. The primers used for E1 were: 5´- ggg gaa ttc atg cat cac cat cac cat 6 
cac TAC CAA GTG CGC AAC TCC ACG – 3´ (forward) and 5´- ggg GAT CCG 7 
GAG CAG CTG AGC – 3´ (reverse). For E2 the primers used were: 5´- gcc atg GGC 8 
GTC GAC CCG GAA ACC CAC – 3´ (forward) and 5´- g ggc ggc cgc tta gtg atg 9 
gtg atg gtg atg aga tct CTC GGA CCT GTC CCT GTC - 3´ (reverse). Bases in 10 
uppercase letters indicate sequences of E1 and E2. Bases in bold lowercase letters 11 
denote codons for 6xHis tags added to the amino terminus of E1 and to the carboxy 12 
terminus of E2 ectodomains. Two restrictions sites (underlined), EcoRI and BamHI 13 
for E1, NcoI and NotI for E2, were created at the 5´ and 3´ ends of both ectodomain 14 
genes. In order to connect E1 and E2 ectodomains by a flexible FLAG peptide, the 15 
E2 gene was subcloned into the pET30a plasmid (Novagen) digested with NcoI and 16 
NotI. The pET30a vector contains the sequence encoding the enterokinase 17 
recognition site, which is part of the FLAG tag, upstream of the cloning site. The 18 
resulting plasmid, pET30-E2 was used as template for a third PCR reaction using the 19 
same E2 reverse primer and the following forward primer: 5´ - c ggg atc cca gac tac 20 
aag gac gac gac gac aag – 3´; this oligonucleotide introduces the complete sequence 21 
codifying the FLAG peptide (in bold lowercase letters) as well as a BamHI restriction 22 
site (underlined). Finally both amplified ectodomain cDNAs were digested with their 23 
corresponding restriction endonucleases (EcoRI and BamHI for E1, BamHI and NotI 24 
for FLAG-E2) and cloned into the EcoRI/NotI digested pAcGP67A baculovirus 25 
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transfer vector (Pharmingen) in a three fragment ligation to create pAcGP67A-1 
E1341E2661. 2 
Insect cell culture and transfections 3 
  The insect cell line Spodoptera frugiperda (Sf9) was cultured in Insect X-4 
Press serum-free media (BioWhittaker) at 27 ºC. Sf9 cells were cotransfected with 5 
BaculogoldTM DNA (Pharmingen) and the recombinant transfer vector pAcGP67A-6 
E1341E2661 as indicated by the manufacturer. BaculogoldTM DNA is a modified wild 7 
baculovirus DNA which contains a lethal deletion and cannot develop into a viable 8 
virus by itself. Recombination between the flanking regions of the polyhedrin gene 9 
from the transfer vector and modified wild-type baculovirus DNA therefore results in 10 
100% recombinant baculovirus DNA. Several rounds of culture amplified the 11 
recombinant virus, and a high titer virus stock solution was harvested. To express the 12 
protein on a larger scale, High FiveTM insect cells (Invitrogen) were grown in Insect 13 
X-Press serum-free media prior to infection with high titer virus (>108 pfu/ml) at a 14 
multiplicity of infection of 5-10. 15 
 16 
Purification of E1341E2661 17 
  Typically, 500 ml of recombinant baculovirus-infected insect cell cultures 18 
were harvested approximately 120 h postinfection and the cells pelleted by 19 
centrifugation at 5000 g for 10 min. The supernatant was dialyzed against 20 mM 20 
Tris-HCl pH 7, 50 mM NaCl and loaded onto a Ni2+-Nitrilotriacetic acid agarose (Ni-21 
NTA-agarose) column (Qiagen) which had been previously equilibrated with the 22 
same buffer. About 3 ml of gel were used per liter of culture supernatant. The flow 23 
rate was adjusted to 0.5 ml/min. Once the protein solution had entered the column, it 24 
was washed with dialysis buffer containing 10 mM imidazole and later 30 mM 25 
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imidazole. The recombinant E1341E2661 protein was eluted with 200 mM imidazole in 1 
dialysis buffer. The presence of E1341E2661 was monitored by SDS-PAGE throughout 2 
the purification. 3 
 4 
Protein analysis 5 
 Protein concentrations were determined spectrophotometrically from the 6 
absorbance at 280 nm and the extinction coefficient calculated from the amino acid 7 
analysis. The absorption spectra were recorded on a Beckman DU-640 8 
spectrophotometer. The amino acid analysis of hydrolyzed aliquots was performed on 9 
a Beckman 6300 automatic analyzer. Approximately 20 g of purified protein were 10 
hydrolyzed with 5.9 N tridistilled HCl at 110 ºC for 24 h. Norleucine was used as an 11 
internal standard. Automated Edman protein degradation of E1341E2661 was 12 
performed using an Applied (model 494) gas-phase sequencer. 13 
 14 
SDS-PAGE 15 
  Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was 16 
performed according to Laemmli using 15% polyacrylamide gels [34]. Samples were 17 
subjected to gel electrophoresis under either nonreducing or reducing conditions 18 
(with 5% (v/v) -mercaptoethanol) and the proteins were stained with Coomassie 19 
brilliant blue R-250. The molecular mass of the protein bands was estimated by 20 
comparison with protein markers of known molecular mass (Prestained SDS-PAGE 21 
Standards, Bio-Rad). 22 
 23 
Western blotting 24 
 9
After SDS-PAGE, proteins were transferred to nitrocellulose membranes 1 
(Hybond-ECL; Amersham) in 48 mM Tris-HCl, pH 9.0, containing 39 mM glycine, 2 
0.0375% SDS and 20% (v/v) methanol, for 1 h at 1 mA/cm2, by using a V20-SDB 3 
apparatus (Scie-Plas). To detect E1341E2661, membranes were incubated with a HRP-4 
conjugated monoclonal anti-His (Sigma) or anti-FLAG (Sigma) at a 1:3000 dilution. 5 
The peroxidase reaction was developed with 3,3’-diaminobenzidine 6 
tetrahydrochloride/H2O2. For the detection of the recombinant protein with the mouse 7 
anti-E1 (USBiologicals) and rabbit anti-E2661 antibodies, nitrocellulose membrane 8 
was incubated with these antibodies diluted 1:1000 with 0.1% Tween 20 in PBS. 9 
Following overnight incubation at 4 ºC, the membrane was washed extensively with 10 
PBS containing 0.1% Tween 20. The membrane was then incubated with a goat anti-11 
mouse or goat anti-rabbit antibody diluted 1:3000 for 2 hours. After membrane 12 
washing, the immunoblots were developed as described above. When the membranes 13 
were incubated with individual sera from HCV-positive human patients, E1341E2661 14 
was detected via Enhanced Chemiluminiscence (ECL). After blotting, the membrane 15 
was incubated with the human sera diluted 1:20, washed and incubated with HRP-16 
conjugated anti-human IgG (Fc) (Sigma) diluted at 1:1000. E1341E2661 was detected 17 
by incubating the membranes with ECL reagents (Amersham Life Sciences) and 18 
exposure to photographic film. The volumes of the bands were estimated by 19 
densitometry using UVIBand V97 (UVItec) 20 
Polyclonal antibody against recombinant protein, E2661 [30], was prepared by 21 
immunizing New Zealand white rabbits over a 6-week period by weekly injection of 22 
the protein (100 μg) in complete Freund´s adjuvant. 23 
 24 
Protein Deglycosylation 25 
 10
  Protein samples were digested with N-glycosidase F (PNGase F, Roche). 1 
Digestion was carried out for 16 h at 37 ºC in 20 mM sodium phosphate, pH 7.0, 50 2 
mM EDTA, and 1% (p/v) octylglucoside. Digested samples were mixed with 3X 3 
Laemmli sample buffer and analyzed by SDS-PAGE. The proteins were stained with 4 
Coomassie brilliant blue R 250. The proteins were also transferred to nitrocellulose 5 
membranes that were subsequently incubated with the lectin concanavalin A 6 
conjugated to biotin. The glycoproteins were detected using HRP-streptavidin at a 7 
1:1000 dilution. 8 
 9 
Circular Dichroism 10 
  CD measurements were carried out on a Jasco spectropolarimeter, model J-11 
715. All the measurements were conducted at 25 ºC with cells thermostated with a 12 
Neslab RTE-111 water bath. Far-UV CD spectrum was measured at a protein 13 
concentration of 0.15 mg/ml using protein dialyzed against 20 mM Tris-HCl pH 7, 50 14 
mM NaCl. The pathlength was 1 mm. Five scans were averaged for each 15 
measurements and the contribution of the buffer was always subtracted. The spectra 16 
were calculated by using 110 as the mean residue molecular mass and the results are 17 
expressed in terms of residue molar ellipticity in degcm2dmol-1. The secondary 18 
structure of the protein was evaluated by computer fit of the dichroism spectra 19 
according to Convex Constraint Analysis (CCA) [35]. This method relies on an 20 
algorithm that calculates the contribution of the secondary structure elements that 21 
give rise to the original spectral curve without referring to spectra from model 22 
systems. The secondary structure was also predicted by the GOR IV method [36].  23 
 24 
Fluorescence spectroscopy 25 
 11
  Emission spectra were obtained at 25 ºC using an SLM AMINCO 8000C 1 
spectrofluorimeter, fitted with a 450-W xenon arc. Excitation and emission slit widths 2 
were set at 4 nm. The protein concentration was 0.05 mg/ml and a 0.4 x 1 cm cuvette 3 
was used. Buffer was 20 mM Tris-HCl pH 7, 50 mM NaCl. Excitation was performed 4 
at 275 or 295 nm, and the emission spectra were recorded over the range 285-450 nm. 5 
The contribution of the buffer was always subtracted. The tyrosine contribution to the 6 
emission spectra was calculated by subtracting the emission spectrum measured at 7 
exc = 295 nm multiplied by a factor from that measured at exc = 275 nm. The factor 8 
was obtained from the ratio between the fluorescence intensities measured with exc = 9 
275 and exc = 295 nm at wavelengths above 380 nm, where there is no tyrosine 10 
contribution. 11 
  12 
 Analytical ultracentrifugation 13 
  The sedimentation velocity experiments were carried out on a Beckman 14 
Optima XL-A analytical ultracentrifuge equipped with UV-VIS optics detection 15 
system, using an An60Ti rotor and 12 mm double-sector centerpieces. The 16 
experiments were done with a protein concentration of 5 M. They were carried out 17 
at 20 ºC. The buffer employed was 20 mM Tris-HCl pH 7, 50 mM NaCl. The 18 
sedimentation coefficient distributions were calculated by modelling on the 19 
sedimentation velocity data using the c(s) method [37], as implemented in the 20 
SEDFIT program, from which the corresponding sedimentation coefficients (s-21 
values) were obtained. 22 
 23 
Enzyme Linked Immunosorbent Assay (ELISA) 24 
 12
 96 wells microtitre plates (Costar 3690) were coated overnight at 4 ºC with 1 
100 ng/well of purified recombinant E1341E2661 diluted to 1 g/ml in 0.05 M 2 
carbonate-bicarbonate buffer, pH 9.6. Unbound antigen was washed out, and the 3 
wells were blocked with 3% non-fat dry milk in PBS for 60 min at room temperature. 4 
After washing the wells were incubated at 37ºC for 2 h with HCV-positive and 5 
negative human sera. Seven positive and seven negative sera were used at a dilution 6 
of 1:200. The plates were then washed three times with PBS/0.05% Tween 20 and 7 
incubated at 37ºC for 1 h with HRP-conjugated anti-human IgG (Fc) diluted at 8 
1:10.000. Bound antibodies were detected by adding 100 mM sodium citrate, pH 5.0, 9 
4% Methanol buffer containing H2O2 and the substrate o-phenylenediamine 10 
dihydrochloride (Merck). The optical density at 492 nm was measured using an 11 
ELISA Expert 96 microplate reader (ASYS Hitech). The absorbance values obtained 12 
with a preimmune serum were subtracted. ELISA inhibition assays were performed 13 
as described in [38]. After coating with 100 μl of antigen (1g/mL), the plates were 14 
incubated with HCV infected patients sera (diluted 1:20) previously mixed with 15 
different dilutions of the inhibitor (rabbit anti-E2661 serum or monoclonal anti-E1) 16 
(10-6-10-1). Binding of human IgG was detected as described above. The inhibition 17 
data were normalized to inhibition of binding by pre-immune serum. Sera from 18 
infected and control patients were provided by Dr. Fernando Vivanco (Fundación 19 
Jiménez Díaz, Madrid, Spain). 20 
 21 
Immunoprecipitation 22 
 A 50 l aliquot of rabbit anti-mouse immunoglobulin G bound to Sepharose 23 
beads (Pharmacia-LKB) was incubated with either 2 l of anti-E2 monoclonal 24 
antibody H53, 2 l of anti-E1 monoclonal antibody (USBiological) or 2 l of rabbit 25 
 13
serum for 1 h at 4 ºC in 10 mM Tris-Cl, pH 7.5, containing 0.2% NP-40, 150 mM 1 
NaCl and 2 mM EDTA (TBS-NP-40). The MAb H53 is conformation-dependent and 2 
was a generous gift of Dr. Jean Dubuisson. Beads were then incubated with 2 g of 3 
purified E1341E2661 for 1 h at 4ºC. Between each step, the beads were washed twice 4 
with TBS–NP-40. After the last step, they were washed three times with this buffer 5 
and once with distilled water. The precipitates were then boiled for 5 min in SDS-6 
PAGE sample buffer and analyzed on a 12% polyacrylamide gel. After 7 
electrophoresis and transfer to nitrocellulose membranes, protein E1341E2661 was 8 
detected by incubating the membranes with a polyclonal goat anti-E2 antibody 9 
(USBiological) at a 1:500 dilution followed with a rabbit anti-goat antibody 10 
conjugated to HRP diluted at 1:3000. The peroxidase reaction was developed with 11 
3,3’-diaminobenzidine tetrahydrochloride/H2O2. 12 
 13 
14 
 14
Results 1 
Expression and purification of E1341E2661 2 
Recombinant E1341E2661 has 466 amino acids, 150 corresponding to positions 3 
192 to 341 of E1, 278 corresponding to positions 384 to 661 of E2 and the rest being 4 
due to the cloning strategy, the FLAG sequence between E1 and E2 and the His tags 5 
used to purify the recombinant protein (Fig. 1). 6 
The chimeric protein E1341E2661 was expressed in High FiveTM insect cells 7 
transfected with the pAcGP67A-E1341E2661 plasmid along with wild-type viral DNA. 8 
In a homologous recombination event, the E1341E2661 gene was inserted into the viral 9 
genome. The protein was expressed by infecting a new batch of insect cells using 10 
amplified recombinant virus. Cells were grown and protocols were carried out as 11 
described in Materials and methods. The analysis of the different fractions with a 12 
HRP conjugate anti-His antibody showed that the protein was produced soluble both 13 
intracellularly and in the extracellular medium (Fig. 2A, lanes 1, 2). Moreover, after 14 
cell lysis by sonication, it was observed that the protein was also able to form 15 
insoluble inclusion bodies (Fig. 2A, lane 3). Only the protein which was expressed in 16 
a soluble form and secreted to the extracellular medium was subsequently purified 17 
using affinity chromatography on a Ni-nitrilotriacetic acid-agarose column (Fig. 2B). 18 
The protein that elutes with 200 mM imidazole was determined to be > 95% pure by 19 
densitometry of stained SDS gels. Following this procedure, approximately 2 mg of 20 
E1341E2661 protein were obtained from 1 L of culture media. The purified protein was 21 
recognized by the monoclonal anti-FLAG as well as by a monoclonal anti-E1 22 
antibody and the polyclonal anti-E2661 antibody (Fig. 2C). 23 
 24 
 25 
 15
Biochemical characterization of E1341E2661 1 
The amino acid composition of the recombinant protein determined by amino 2 
acid analysis was coincident with that deduced from the cDNA sequence (data not 3 
shown). The absorption spectrum was characteristic of a soluble protein with a 4 
maximum at 280 nm and a shoulder at 290 nm. The extinction coefficient calculated 5 
from the spectrum and using the protein concentration calculated from the amino acid 6 
analysis was 110342 M-1cm-1. Moreover, the Edman degradation of the purified 7 
protein confirmed the sequence of the first six amino-terminal amino acids of 8 
E1341E2661: ADPGYL. This result showed that the signal peptide gp67 had been 9 
correctly cleaved by cellular proteases, giving rise to the secretion of the processed 10 
protein. 11 
 SDS-PAGE of the recombinant protein in the presence of reducing agents 12 
showed a single band with a molecular mass of 64 kDa (Fig. 3A, lane 2) while the 13 
theoretical mass based on the amino acid sequence is 51.5 kDa. Then, E1341E2661 may 14 
be glycosylated in the 5/6 and 11 potential glycosylation sites of E1 and E2, 15 
respectively [6], most of which are well-conserved [6, 39]. In fact, when the 16 
recombinant protein was treated with PNGase F, which releases asparagine-linked 17 
(N-linked) oligosacharides from glycoproteins, the molecular mass of E1341E2661 18 
decreased to 55 kDa (Fig. 3A, lane 3). Nevertheless, carbohydrates were still detected 19 
with concanavaline A in the recombinant protein treated with PNGase F (Fig. 3B, 20 
lane 2), indicating either that E1341E2661 contain N-glycosidic bonds which are not 21 
accessible to PNGase F or the existence of O-glycosidic bonds. 22 
We have used sedimentation velocity to determine the oligomeric nature of 23 
E1341E2661 (Fig. 4). The calculated molecular mass of the most abundant species was 24 
150 kDa with a sedimentation coefficient of 7s. Considering that the expected 25 
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molecular mass of the E1341E2661 monomer determined by SDS-PAGE is 64 kDa, the 1 
main form observed by ultracentrifugation is compatible with a dimer (Fig. 4, peak 2 
b). However, the recombinant protein was also present as monomer (Fig. 4, peak a) 3 
and higher order oligomers formed by more than two units of monomers, such us 4 
trimers (peak c), tetramers (peak d) and other higher forms (peaks e, f and others not 5 
shown) (Fig. 4). Based on the area under each peak the following proportion of each 6 
form was estimated:  13% monomer, 31 % dimer, 17% trimer and 13% tetramer. The 7 
analysis of the recombinant protein by SDS-PAGE in the absence of reducing agents 8 
also indicated the oligomeric nature of the purified protein (Fig. 4, inset). Under these 9 
conditions only monomers, dimers and trimers were observed while a high 10 
percentage of the protein does not enter into the gel. 11 
 12 
Spectroscopic analysis of E1341E2661 13 
The spectroscopic characterization of E1341E2661 was carried out by means of 14 
circular dichroism and fluorescence spectroscopies. The far-UV CD spectrum of 15 
E1341E2661 showed a minimum at 208 nm and a shoulder at 223 nm (Fig. 5). 16 
Deconvolution of this spectrum using the program Convex Constraint Analysis 17 
(CCA) [35] yielded the following percentages of secondary structure elements: 13% 18 
-helix, 48% -sheet, and 39% non-ordered structure. The predictive GOR IV 19 
method [36], which is based upon the propensity of each amino acid to adopt a 20 
particular secondary structure, yielded similar results: 8% -helix, 32% -sheet and 21 
60% non-ordered structure. 22 
The fluorescence emission spectrum of E1341E2661 is depicted in Figure 6. 23 
Upon excitation at both 275 and 295 nm, the recombinant protein exhibited a 24 
maximum at 331 nm. The shape of the spectrum indicates that the fluorescence of 25 
 17
this protein is highly dominated by tryptophan residues. In fact, the difference 1 
between the fluorescence spectra obtained upon excitation at 275 and 295 nm, the 2 
latter being normalized, indicates that the contribution of tyrosine residues to the 3 
recombinant protein fluorescence upon excitation at 275 nm was very low, 4 
approximately 5%. The position of the maximum indicates that the tryptophan 5 
residues occupy a relatively low hydrophobic environment. When the protein is 6 
treated with 8 M urea, the fluorescence intensity increased by 15% and the maximum 7 
is red shifted to 345 nm (Fig. 6).  8 
 9 
Antigenic characterization of E1341E2661 10 
A panel of seven HCV-positive and seven HCV-negative human sera was 11 
used to assess the antigenic properties of E1341E2661. The recombinant protein was 12 
able to bind under native conditions to antibodies present in all seven positive sera 13 
tested as assessed by ELISA (Fig. 7, sera 1-7). The values of the absorbance at 492 14 
nm were much higher than those obtained with the negative controls (Fig. 7, serum 8; 15 
only one negative serum is depicted). Moreover, the difference in the values of the 16 
absorbance is consistent with the HCV titer as determined by COBAS TaqMan HCV 17 
test [40] (data not shown). On the other hand, the same sera were used in 18 
immunoblotting experiments after protein separation by SDS-PAGE (Fig. 7, inset). 19 
The data were quantified by densitometry. The volumes were normalized with respect 20 
to that obtained with serum 3 which gave the highest value (Figure 7, inset). There 21 
was no correlation between these values and those obtained by ELISA. Thus, sera 1, 22 
4 and 7 which are among the ones that gave the highest absorbance values in ELISA 23 
were the ones which yielded the lowest volume values (approximately 30% of that of 24 
serum 3 which, on the other hand, yielded one of the lowest values in ELISA). This is 25 
 18
indicative of the existence of both continuous and discontinuous epitopes, the latter 1 
being the ones which are lost under denaturing conditions. 2 
The conformation of the chimeric protein was examined by 3 
immunoprecipitation with the monoclonal anti-E2 antibody H53, and with a 4 
monoclonal antibody anti-E1. The E1341E2661 protein was efficiently 5 
immunoprecipitated by both antibodies. Since H53 is a conformation-dependent 6 
monoclonal antibody, it can be assumed that the E2 moiety of the chimeric 7 
recombinant protein possesses a native-like conformation. When the 8 
immunoprecipitated protein was analyzed by SDS-PAGE in the absence of reducing 9 
agents, the same pattern of bands shown in the inset of Figure 4, lane 2 was observed. 10 
In consequence it can be stated that all the oligomeric forms were able to react with 11 
the monoclonal antibody. The recombinant protein was able to bind to Huh7 cells and 12 
when the binding was performed in the presence of anti-CD81 it was drastically 13 
reduced (data not shown). 14 
In order to distinguish the presence of anti-E1 and anti-E2 antibodies in the 15 
sera of infected individuals, an inhibition experiment using a polyclonal anti-E2661 16 
antibody was carried out (Fig. 8). The presence of an excess of rabbit anti-E2 17 
antibodies would prevent the binding to E1341E2661 of the anti-E2 antibodies present 18 
in the HCV-positive sera. Several dilutions of the polyclonal anti-E2 were assayed. 19 
Taking sera 5 and 7 as examples, the binding of IgGs to E1341E2661 was practically 20 
abolished by the anti-E2661 antibody from a dilution of 10-3, although their patterns of 21 
inhibition are markedly different (Fig. 8A). To assure maximum inhibition, the rest of 22 
the sera were mixed with a 10-1 dilution of the anti-E2661 antibody. At this value, 23 
inhibition studies showed that the polyclonal anti-E2661 antibody blocked the binding 24 
of the IgGs from the seven HCV-positive sera to different levels (Fig. 8B), the 25 
 19
average being of inhibition 72 % (Fig. 8, horizontal line). To assess the presence of 1 
both anti-E1 and anti-E2 IgGs in the serum of the infected individuals, the same 2 
experiment was carried out in the presence of an excess of monoclonal anti-E1 and 3 
using sera 3 and 5 as examples. When these sera were incubated with a 10-1 dilution 4 
of monoclonal anti-E1, an 80% inhibition was observed for serum 3 while only a 5 
15% inhibition was observed for serum 5. Thus, serum 3 would contain mainly 6 
antibodies which bind to E1 while those antibodies present in serum 5 would bind to 7 
E2. Consequently, and although the number of sera may not be statistically 8 
significant, the response to each envelope protein would depend on the infected 9 
individual. 10 
11 
 20
Discussion 1 
Hepatitis C virus encodes two enveloped glycoproteins, E1 and E2, which are 2 
involved in viral attachment and entry into target cells as well as in the fusion of viral 3 
and cellular membranes [41-44]. Most of the knowledge concerning the structural 4 
properties of these proteins is based on transient expression experiments. Their 5 
implication in the infection mechanism has also been investigated using different 6 
surrogate systems such as HCV-like particles, HCV pseudotype retroviral particles or 7 
replication-competent recombinant vesicular stomatitis virus encoding HCV 8 
envelope proteins [21, 45, 46].  9 
However, the reports about the properties of isolated proteins are scarce. 10 
Previous attempts have been made to obtain the ectodomains of the proteins E2 and 11 
E1 separately. Expression in Escherichia coli led to the production of inclusion 12 
bodies which can only be solubilized with chaotropic agents. In the case of E2 the 13 
non-glycosylated recombinant protein thus obtained was able to interact with the 14 
virus receptor CD81 and it was recognized by a number of well-characterized anti-15 
E2 antibodies in a similar way to that of native glycosylated forms [25, 47]. The 16 
structural proteins of HCV have also been produced in mammalian expression 17 
system [48, 49], yeast cells and recombinant baculovirus-infected insect cells [25, 29, 18 
30, 50, 51]. In all cases, the majority of the recombinant proteins exhibit a molecular 19 
mass much higher than that expected because of the hyperglycosylation of the 20 
protein. In the case of E1341, this protein was recently obtained from yeast and 21 
mammalian cells as a cysteine-blocked monomer only in presence of a detergent or 22 
reconstituted as 100 nm-particles when the detergent was eliminated [29]. 23 
Another strategy towards the understanding of the structure-function 24 
relationship of HCV envelope proteins is to obtain a tandem chimeric protein based 25 
 21
on HCV E1 and E2 envelope glycoproteins. In this report we have achieved the 1 
expression and purification of a chimeric recombinant protein, E1341E2661, containing 2 
the ectodomains of E1 and E2 linked by a hydrophilic and flexible FLAG region. To 3 
overcome the hyperglycosylation problems encountered in yeast, we have expressed 4 
E1341E2661 using a baculovirus expression system. Among others, it has the 5 
advantage of producing the protein in large amounts, and also the system leads to 6 
post-translational modifications which are similar to those observed in mammalian 7 
cells. Thus, by using High FiveTM insect cells we have obtained the E1341E2661 8 
protein secreted to the extracellular medium. After purification by affinity 9 
chromatography on Ni-NTA-agarose, we obtained, approximately, 2 mg of 10 
E1341E2661/liter of media. As evidenced below, this protein possesses all the features 11 
of a native soluble protein. 12 
We have also expressed the same sequence both in E. coli and yeast cells 13 
(data not shown). The protein was produced in bacteria in a really high yield as an 14 
insoluble 50 kDa polypeptide but all attempts to solubilize it failed. In this respect, 15 
although it has been recently described the purification and application of bacterially 16 
expressed chimeric protein E1E2 [52], after purification in the presence of 6 M urea, 17 
the protein had to be dialyzed in the presence of both 0.1% Triton X-100 and 0.2% 18 
BSA which precludes any subsequent structural study. By using the yeast Pichia 19 
pastoris a highly glycosylated and insoluble non secreted protein was obtained. 20 
Taken together, these facts indicate that the proper glycosylation is an indispensable 21 
factor for the global folding of this structural protein. In fact, it has been reported that 22 
the glycans of HCV envelope glycoproteins play a major role in protein folding 23 
and/or in HCV entry [53-55]. 24 
 22
The E1341E2661 protein used throughout this study was secreted to the cellular 1 
medium by virus-infected insect cells. However, it was also produced intracellularly 2 
in both soluble and insoluble forms which were more heterogeneous in size than the 3 
secreted one. This may be indicative that only the properly folded and processed 4 
polypeptide chains are able to enter the secretion pathway. On the other hand, the E1 5 
and E2 ectodomains are separated by a hydrophilic sequence which contains the 6 
FLAG sequence with the enterokinase cleavage sequence which could be used to 7 
obtain both domains in a separate and soluble form. Nevertheless, all attempts to 8 
cleave that peptide bond failed.  9 
The deconvolution of the circular dichroism far-UV spectrum of the 10 
recombinant E1341E2661 protein showed that -sheet is the major ordered secondary 11 
structure element. The percentages of secondary structure deduced from the CD 12 
spectrum are coincident with those deduced from the amino acid sequence. 13 
Moreover, the fluorescence emission maximum corresponding to the tryptophan 14 
residues of the protein is centered at 331 nm, indicating that these residues are 15 
located in a moderately hydrophobic environment. Upon denaturation with urea, this 16 
maximum is red-shifted to 345 nm which is the value described for Trp residues in 17 
aqueous solution. Besides, the quantum yield of Trp residues undergoes a 18 
considerable increase which would indicate that the Trp fluorescence is quenched by 19 
nearby residues in the native conformation but not in the open and denatured 20 
conformation observed in the presence of urea. In consequence, the spectroscopic 21 
properties of the secreted protein are those of a three-dimensionally structured 22 
protein. 23 
 We have also evaluated the ability of E1341E2661 to bind to human antibodies 24 
with a panel of HCV-positive human sera by both ELISA and immunoblotting. 25 
 23
Under the conditions employed in ELISA assays the recombinant protein maintains 1 
its native conformation and the IgGs recognize both lineal and discontinous epitopes. 2 
However, in presence of SDS and β-mercaptoethanol, conditions employed in 3 
immunoblotting, the protein is completely unfolded and only the lineal epitopes are 4 
those which are recognized by IgGs. E1341E2661 was able to bind to the antibodies 5 
present in all HCV-positive sera tested. Reduction and denaturation of the 6 
recombinant protein diminished the binding to some of the sera, although to a 7 
different extent, indicating the presence of both continuous and discontinuous 8 
epitopes that need the correct network of disulfide bridges to maintain its 9 
conformation. 10 
E1 and E2 HCV envelope glycoproteins have been shown to form 11 
noncovalent heterodimers as well as heterogeneous disulfide-linked aggregates [56, 12 
57]. Characterization of the noncovalent heterodimer with conformation dependent 13 
monoclonal antibodies has suggested that this oligomer is likely the prebudding form 14 
of the functional complex [58]. Moreover, E1 and E2 glycoproteins interact to 15 
constitute oligomeric complexes which are the functional subunits of the HCV virion 16 
[56]. On the other hand, it has been suggested that the disulfide-linked aggregates are 17 
a consequence of an inefficient folding of HCV envelope proteins [59]. We have 18 
used analytical ultracentrifugation experiments to study the oligomeric nature of 19 
E1341E2661. The obtained results are indicative of a high tendency to self-associate, 20 
property that has already been reported [60]. The dimer is the most abundant species 21 
present in solution under the conditions employed, although higher order oligomers 22 
are also present. These E1341E2661 homodimers have to be maintained by 23 
hydrophobic interactions which are disrupted by SDS when the protein is analyzed in 24 
SDS-PAGE in the absence of reducing agents. However, disulfide bridges must be 25 
 24
involved as well in the formation of the dimer and the other oligomeric species 1 
which are also observed under these conditions. On the other hand, all the oligomeric 2 
species observed for the recombinant chimeric protein maintain a correctly folded 3 
conformation as assessed with the conformation-dependent monoclonal antibody 4 
H53 directed against the E2 ectodomain, and are not just mere aggregates with 5 
unfolded conformation. Another proof of the correct conformation of the chimeric 6 
protein is the fact that it was also able to bind to human hepatome Huh7 cells through 7 
CD81 which has been described as a cellular receptor. 8 
Although there are several lines of evidence that indicate that E1 and E2 have 9 
separable functional properties, to have both ectodomains in a single polypeptide 10 
chain would have advantages over the separated domains. For instance, it has been 11 
described that both envelope proteins are required for maximal infection by HCV 12 
[61, 62]. Besides, Michalak and coworkers have shown that the folding of E1 is 13 
helped by the coexpression of E2 [28]. Moreover, two earlier studies indicate that 14 
HCV envelope glycoproteins cooperate for the formation of a functional complex 15 
and that both glycoproteins have to be co-expressed to analyze their functional 16 
properties [63, 64]. Taking into account the results described in this manuscript, it 17 
seems safe to state that E1341E2661 recombinant protein is properly folded and, at 18 
least in the E2 moiety, presents antigenic properties similar to those in the HCV 19 
virion. This chimeric soluble polypeptide chain formed by E1 and E2 ectodomains 20 
may be a valuable tool to study the structure-function relationship of HCV envelope 21 
proteins, comparable to other surrogate systems such as HCV-like particles [45], 22 
HCVpp [21] or E1E2-liposomes [33] as well as in the development of future 23 
vaccines.  24 
25 
 25
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Figure captions 1 
 2 
Fig. 1. Amino acid sequence of E1341E2661. Amino acids shown in bold are those 3 
which belong to E1 and E2 while those underlined are introduced by cloning. 4 
Positions 1 to 16 of the recombinant protein are due to cloning and to the 6xHis used 5 
to purify it. DYKDDDDK is the FLAG sequence which contains the sequence 6 
DDDDK which is recognized by enterokinase. Residues 175-176, AM , are 7 
introduced by the cloning procedure. Positions 177 to 180 of the recombinant protein 8 
correspond to residues 380 to 383 of E1. The sequence RSHHHHHH was used to 9 
increase the possibility to purify the protein by affinity chromatography.  10 
 11 
Fig. 2. Analysis of the expression of E1341E2661 by High FiveTM cells. (A) Western 12 
blot analysis of the extracellular (lane 1) and the intracellular soluble (lane 2) and 13 
insoluble (lane 3) E1341E2661 produced by baculovirus infected insect cells. After 14 
transferring to nitrocellulose membranes, proteins were detected with a peroxidase-15 
conjugated monoclonal anti-His antibody as described in the Materials and methods 16 
section. (B) SDS-PAGE of purified E1341E2661 recombinant protein (lane 2). The 17 
samples were previously reduced with 5% (v/v) -mercaptoethanol and boiled for 5 18 
min. The gel was stained with Coomassie Brilliant blue R-250. Protein size markers 19 
(lane 1). (C) Western blot analysis of purified E1341E2661 using three different 20 
antibodies: a monoclonal antibody raised against FLAG region, a monoclonal against 21 
E1 glycoprotein, and a rabbit anti-E2661 antibody.  22 
 23 
Fig. 3.  Analysis of the deglycosylation of E1341E2661 by PNGase F. (A) SDS-PAGE 24 
stained with Coomassie blue. (1) Protein size markers; (2) Purified E1341E2661; (3) 25 
 36
E1341E2661 treated with PNGase F; (B) SDS-PAGE stained with concanavalin A. (1) 1 
Purified E1341E2661; (2) E1341E2661 treated with PNGase F. Digestion with PNGase F 2 
was carried out for 16 h at 37 ºC in 20 mM sodium phosphate, pH 7.0, 50 mM 3 
EDTA, and 1% (v/v) octylglucoside. After transferring, the nitrocellulose 4 
membranes were incubated with biotinylated concanavalin A and the proteins were 5 
detected using peroxidase-conjugated streptavidin as described in the Materials and 6 
methods section.  7 
 8 
Fig. 4. Sedimentation velocity analysis of E1341E2661. The results are shown as the 9 
sedimentation coefficient distribution c(s). The experiment was carried out at 5 M 10 
native E1341E2661. (a) monomer, (b) dimer, (c) trimer, (d) tetramer. (Inset) SDS-11 
PAGE in the absence of reducing agents. (1) Protein size markers, (2) Purified 12 
E1341E2661. The positions of (a) monomer, (b) dimer, (c) trimer are marked. The gel 13 
was stained with Coomassie Brilliant blue R-250. 14 
 15 
Fig. 5.  Far-UV circular dichroism spectrum of E1341E2661. The spectrum was 16 
recorded between 190 and 250 nm with a protein concentration of 0.15 mg/ml in a 17 
cylindrical cuvette of 0.1 cm pathlength. The buffer was Tris-HCl 20 mM, pH 7.0, 50 18 
mM NaCl. The spectrum was recorded five times, averaged and corrected for buffer 19 
contributions. Data were collected at 25 ºC and are expressed as residue molar 20 
ellipticity. 21 
 22 
Fig. 6.  Fluorescence emission spectra of E1341E2661. The excitation wavelength was 23 
275 nm (     ) and 295 nm (---). The emission spectra were recorded between 300 and 24 
450 nm. The spectrum obtained after excitation at 295 nm was normalized at 25 
 37
wavelengths above 380 nm. The contribution of Tyr residues () to the emission 1 
spectrum was calculated as described in the Materials and methods section. Protein 2 
concentration was 0.05 mg/ml. The buffer was Tris-HCL 20 mM, pH 7, NaCl 50 3 
mM. The spectrum in the presence of 8 M urea was also recorded (–  –). Spectra 4 
were collected at 25 ºC. The contribution of the buffer was always subtracted.  5 
 6 
Fig. 7.  ELISA with HCV-positive human sera. Microtitre wells were coated 7 
overnight at 4 ºC with E1341E2661 recombinant protein at 100 ng/well. Seven HCV-8 
positive human sera (1-7) and one HCV-negative human sera (8) were used at a 9 
dilution of 1:20. Bound antibodies were detected with peroxidase conjugated anti-10 
human IgG (Fc) diluted at 1:10000 as described in the Materials and methods 11 
section. The absorbance values were normalized to that of serum 3 which was taken 12 
as 1.0. The results shown are the mean  standard deviation of three different 13 
experiments. (Inset) Immunodetection of E2661 with HCV-positive human sera. 14 
Purified E1341E2661 was denatured with SDS and -mercaptoethanol. After SDS-15 
PAGE, the proteins were transferred to nitrocellulose membranes which were 16 
incubated with individual sera from HCV-positive patients at a dilution of 1:20. 17 
Finally, the membranes were incubated with peroxidase-conjugate goat anti-human 18 
IgG diluted at 1:10000 and E2661 was detected with ECL detection reagents. The 19 
volumes of the bands, which were quantified by densitometry, are shown above each 20 
band. The data shown are representative of those obtained in three different 21 
experiments. 22 
 23 
Fig. 8.  Inhibition studies of the binding of E1341E2661 to HCV-positive sera. (A) 24 
Inhibition studies of the binding of the IgGs from sera 5 (– –●– –) and 7 (–––○–––) 25 
 38
to the E1341E2661 protein at different dilutions of rabbit anti-E2661 antibody. (B) A 1 
polyclonal rabbit anti-E2661 antibody at 10-1 dilution was used to block the binding of 2 
the recombinant E1341E2661 to IgGs, from 7 HCV-positive sera. The results shown are 3 
the mean  standard deviation of three different experiments. The horizontal line 4 
shows the average of the inhibition of all 7 HCV infected patients sera.  5 
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